Evidence map›Paper›PMID 40386716›Full record

ArticleTranslational lung cancer research2025

Factors predicting early recurrence in patients with unresectable stage III non-small cell lung cancer on durvalumab consolidation after chemoradiotherapy.

Ji Eun Park, Chanmi Kim, Sun Ha Choi, Jong Geol Jang, Kyung Soo Hong, Yong Shik Kwon, Keum-Ju Choi, Jung Seop Eom, Saerom Kim, Hee Yun Seol and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ji Eun Park *Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.
Chanmi Kim *Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Sun Ha ChoiDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.
Jong Geol JangDepartment of Internal Medicine, College of Medicine, Yeungnam University, Daegu, South Korea.
Kyung Soo HongDepartment of Internal Medicine, College of Medicine, Yeungnam University, Daegu, South Korea.
Yong Shik KwonDivision of Pulmonology, Respiratory Center, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.
Keum-Ju ChoiDepartment of Internal Medicine, College of Medicine, Daegu Catholic University, Daegu, South Korea.
Jung Seop EomDepartment of Internal Medicine, College of Medicine, Pusan National University, Busan, South Korea.
Saerom KimDepartment of Internal Medicine, College of Medicine, Pusan National University, Busan, South Korea.
Hee Yun SeolDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, South Korea.
Jehun KimDepartment of Internal Medicine, College of Medicine, Kosin University College of Medicine, Busan, South Korea.
Insu KimDepartment of Internal Medicine, College of Medicine, Dong-A University, Busan, South Korea.
Jin Han ParkDepartment of Internal Medicine, College of Medicine, Inje University, Busan, South Korea.
Tae Hoon KimDepartment of Internal Medicine, School of Medicine, Gyeongsang National University, Changwon, South Korea.
June Hong AhnDepartment of Internal Medicine, College of Medicine, Yeungnam University, Daegu, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Durvalumab consolidation after concurrent chemoradiotherapy (CCRT) is the present standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC). However, some patients experience early recurrence. This study sought risk factors for early recurrence during durvalumab consolidation. Methods: This retrospective multicenter study was conducted between September 2017 and September 2022. We categorized patients into early and non-early recurrence groups. Early recurrence was defined as recurrence within 6 months after the first dose of durvalumab. Results: Of the 222 patients, 40 (18.0%) experienced early recurrence and 182 (82.0%) experienced non-early recurrence. The former group was younger than the latter group (P=0.02). Patients exhibiting lower-level programmed cell death-ligand 1 (PD-L1) expression were more likely to experience early recurrence (P=0.02). Stage IIIC patients tended to experience more early recurrence than stage IIIA/IIIB patients (P=0.055). Multivariate analyses revealed that older age [odds ratio (OR), 0.945; 95% confidence interval (CI): 0.902-0.991; P=0.02] and PD-L1 level ≥50% (OR, 0.303; 95% CI: 0.125-0.736; P=0.008) protected against early recurrence in NSCLC patients on durvalumab consolidation. Median overall survival was significantly longer in the non-early recurrence group than in the early recurrence group (non-evaluable Conclusions: Younger age and lower PD-L1 expression predicted early recurrence during durvalumab consolidation after CCRT. Careful follow-up of such patients is essential.

Indexed as

Chemoradiotherapydurvalumabearly recurrencenon-small cell lung cancer (NSCLC)

Identifiers

PMID40386716
PMCPMC12082245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.